Advertisement

Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial

  • Daniel A Shoskes
    Correspondence
    Reprint requests: Daniel A. Shoskes, M.D., Division of Urology, Harbor-UCLA Medical Center, Box 5, 1000 West Carson Street, Torrance, CA 90502
    Footnotes
    Affiliations
    Institute for Male Urology, Encino, California, USA

    Division of Urology, Harbor-UCLA Medical Center, University of California, Los Angeles, School of Medicine, Torrance, California, USA
    Search for articles by this author
  • Scott I Zeitlin
    Affiliations
    Institute for Male Urology, Encino, California, USA

    Division of Urology, Harbor-UCLA Medical Center, University of California, Los Angeles, School of Medicine, Torrance, California, USA
    Search for articles by this author
  • Asha Shahed
    Affiliations
    Division of Urology, Harbor-UCLA Medical Center, University of California, Los Angeles, School of Medicine, Torrance, California, USA
    Search for articles by this author
  • Jacob Rajfer
    Affiliations
    Institute for Male Urology, Encino, California, USA

    Division of Urology, Harbor-UCLA Medical Center, University of California, Los Angeles, School of Medicine, Torrance, California, USA
    Search for articles by this author
  • Author Footnotes
    1 D. A. Shoskes and J. Rajfer own stock in companies that will benefit from sales of the supplements reported in this study.

      Abstract

      Objectives. The National Institutes of Health (NIH) category III chronic prostatitis syndromes (nonbacterial chronic prostatitis and prostatodynia) are common disorders with few effective therapies. Bioflavonoids have recently been shown in an open-label study to improve the symptoms of these disorders in a significant proportion of men. The aim of this study was to confirm these findings in a prospective randomized, double-blind, placebo-controlled trial.
      Methods. Thirty men with category IIIa and IIIb chronic pelvic pain syndrome were randomized in a double-blind fashion to receive either placebo or the bioflavonoid quercetin 500 mg twice daily for 1 month. The NIH chronic prostatitis symptom score was used to grade symptoms and the quality-of-life impact at the start and conclusion of the study. In a follow-up unblind, open-label study, 17 additional men received 1 month of a supplement containing quercetin, as well as bromelain and papain (Prosta-Q), which enhance bioflavonoid absorption.
      Results. Two patients in the placebo group refused to complete the study because of worsening symptoms, leaving 13 placebo and 15 bioflavonoid patients for evaluation in the blind study. Both the quercetin and placebo groups were similar in age, symptom duration, and initial symptom score. Patients taking placebo had a mean improvement in NIH symptom score from 20.2 to 18.8 (not significant), while those taking the bioflavonoid had a mean improvement from 21.0 to 13.1 (P = 0.003). Twenty percent of patients taking placebo and 67% of patients taking the bioflavonoid had an improvement of symptoms of at least 25%. In the 17 patients who received Prosta-Q in the open-label study, 82% had at least a 25% improvement in symptom score.
      Conclusions. Therapy with the bioflavonoid quercetin is well tolerated and provides significant symptomatic improvement in most men with chronic pelvic pain syndrome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nickel J.C
        Prostatitis.
        Urology. 1998; 51: 362-366
        • Moon T.D
        Questionnaire survey of urologists and primary care physicians’ diagnostic and treatment practices for prostatitis.
        Urology. 1997; 50: 543-547
        • Shoskes D.A
        Effect of the bioflavonoids quercetin and curcumin on ischemic renal injury.
        Transplantation. 1998; 66: 147-152
        • Shoskes D.A
        Use of the bioflavonoid quercetin in patients with longstanding chronic prostatitis.
        J Am Neutraceut Assoc. 1999; 2: 18-21
        • Litwin M.S
        • McNaughton-Collins M
        • Fowler Jr, F.J
        • et al.
        • Chronic Prostatitis Collaborative Research Network
        The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol. 1999; 162: 369-375
        • Tanner M.A
        • Shoskes D
        • Shahed A
        • et al.
        Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and “nonbacterial” prostatitis.
        J Clin Microbiol. 1999; 37: 1863-1870
        • Kaplan S.A
        • Santarosa R.P
        • D’Alisera P.M
        • et al.
        Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option.
        J Urol. 1997; 157: 2234-2237
        • Neal Jr, D.E
        • Moon T.D
        Use of terazosin in prostatodynia and validation of a symptom score questionnaire.
        Urology. 1994; 43: 460-465
        • Barbalias G.A
        • Nikiforidis G
        • Liatsikos E.N
        Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics.
        J Urol. 1998; 159: 883-887
        • Satyanarayana K
        • Shoskes D.A
        A molecular injury-response model for the understanding of chronic disease.
        Mol Med Today. 1997; 3: 331-334
        • de Vries J.H
        • Janssen P.L
        • Hollman P.C
        • et al.
        Consumption of quercetin and kaempferol in free-living subjects eating a variety of diets.
        Cancer Lett. 1997; 114: 141-144
        • Haenen G.R
        • Paquay J.B
        • Korthouwer R.E
        • et al.
        Peroxynitrite scavenging by flavonoids.
        Biochem Biophys Res Commun. 1997; 236: 591-593
        • Chang W.S
        • Lee Y.J
        • Lu F.J
        • et al.
        Inhibitory effects of flavonoids on xanthine oxidase.
        Anticancer Res. 1993; 13: 2165-2170
        • Middleton Jr, E
        • Anne S
        Quercetin inhibits lipopolysaccharide-induced expression of endothelial cell intracellular adhesion molecule-1.
        Int Arch Allergy Immunol. 1995; 107: 435-436
        • Sato M
        • Miyazaki T
        • Kambe F
        • et al.
        Quercetin, a bioflavonoid, inhibits the induction of interleukin 8 and monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha in cultured human synovial cells.
        J Rheumatol. 1997; 24: 1680-1684
        • Mookerjee B.K
        • Lee T.P
        • Lippes H.A
        • et al.
        Some effects of flavonoids on lymphocyte proliferative responses.
        J Immunopharmacol. 1986; 8: 371-392
        • Lee S.C
        • Kuan C.Y
        • Yang C.C
        • et al.
        Bioflavonoids commonly and potently induce tyrosine dephosphorylation/inactivation of oncogenic proline-directed protein kinase FA in human prostate carcinoma cells.
        Anticancer Res. 1998; 18: 1117-1121
        • Hilliard J.J
        • Krause H.M
        • Bernstein J.I
        • et al.
        A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase.
        Adv Exp Med Biol. 1995; 390: 59-69
        • Aziz N.H
        • Farag S.E
        • Mousa L.A
        • et al.
        Comparative antibacterial and antifungal effects of some phenolic compounds.
        Microbios. 1998; 93: 43-54
        • Hollman P.C
        • de Vries J.H
        • van Leeuwen S.D
        • et al.
        Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers.
        Am J Clin Nutr. 1995; 62: 1276-1282
        • Boulton D.W
        • Walle U.K
        • Walle T
        Extensive binding of the bioflavonoid quercetin to human plasma proteins.
        J Pharm Pharmacol. 1998; 50: 243-249
        • Bock U
        • Kolac C
        • Borchard G
        • et al.
        Transport of proteolytic enzymes across Caco-2 cell monolayers.
        Pharm Res. 1998; 15: 1393-1400
        • Canale D
        • Scaricabarozzi I
        • Giorgi P
        • et al.
        Use of a novel non-steroidal anti-inflammatory drug, nimesulide, in the treatment of abacterial prostatovesiculitis.
        Andrologia. 1993; 25: 163-166
        • Hellstrom W.J
        • Schmidt R.A
        • Lue T.F
        • et al.
        Neuromuscular dysfunction in nonbacterial prostatitis.
        Urology. 1987; 30: 183-188
        • Nickel J.C
        • Sorenson R
        Transurethral microwave thermotherapy of nonbacterial prostatitis and prostatodynia.
        Urology. 1994; 44: 458-460
        • Shoskes D.A
        • Zeitlin S.I
        Use of prostatic massage in combination with antibiotics in the treatment of chronic prostatitis.
        Prostate Cancer Prostate Dis. 1999; 2: 159-162